Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Re-Brand, Sell Drug Tests Made by American Bio Medica in POC Setting

NEW YORK (GenomeWeb News) – Nanogen today said it will market point-of-care tests for drugs of abuse made by American Bio Medica into the "hospital-related" setting.
 
Nanogen will re-brand the tests under its Tox STATus name and sell them using its existing sales force and distribution network. American Bio Medica will continue to sell the tests under their original brand to its core criminal justice and workplace markets, a spokesperson for the company said.
 
The tests, which are cleared by US and European regulators, can detect up to 15 commonly abused substances including cocaine, methamphetamine, and marijuana.
 
Nanogen said it expects to begin distributing the tests before the end of the year.
 
Financial terms of the deal were not disclosed.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.